Related Experiment Video

Updated: Apr 11, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

516

MicroRNAs: short non-coding players in cancer chemoresistance

Sara Donzelli1, Federica Mori2, Francesca Biagioni1

  • 1Translational Oncogenomics Unit, Italian National Cancer Institute 'Regina Elena', Via Elio Chianesi 53, 00144 Rome, Italy.

Molecular and Cellular Therapies
|June 10, 2015
PubMed

Insights

MicroRNAs (miRNAs) play a crucial role in cancer chemoresistance by influencing drug sensitivity. Understanding miRNA mechanisms can lead to predictive biomarkers for cancer therapy outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Chemoresistance is a major challenge in cancer therapy.
  • Cancer cells develop resistance through mechanisms like altered drug metabolism and targets.
  • MicroRNAs (miRNAs) are increasingly recognized for their role in modulating cancer drug sensitivity.

Purpose of the Study:

  • To review recent findings on the role of miRNAs in cancer chemoresistance.
  • To elucidate specific miRNA mechanisms contributing to drug resistance.
  • To explore the potential of miRNA profiling as predictive biomarkers.

Main Methods:

  • Literature review of recent studies on miRNAs and chemoresistance.
  • Analysis of molecular mechanisms underlying miRNA-mediated drug resistance.
  • Evaluation of evidence for miRNA profiling in predicting therapy outcomes.

Main Results:

  • miRNAs significantly influence cancer cell sensitivity and resistance to various treatments.
  • Specific miRNAs can promote or inhibit chemoresistance through diverse molecular pathways.
  • miRNA expression profiles show promise as predictive biomarkers for patient response to therapy.

Conclusions:

  • miRNAs are key regulators of cancer chemoresistance.
  • Targeting miRNA pathways may offer novel therapeutic strategies.
  • miRNA profiling holds potential for personalized cancer treatment decisions.
Keywords:
ChemoresistanceMicroRNAMultiple drug resistance

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

858
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.3K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.8K
MicroRNAs01:22

MicroRNAs

12.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K